SEARCH

SEARCH BY CITATION

FilenameFormatSizeDescription
jcmm12300-sup-0001-FigS1-S6-TableS1-S4.docWord document10988K

Figure S1. Quantification of the vascularity index (VI) and vascularity flow index (VFI) detected by 3D power Doppler sonography in women with or without adenomyosis during different menstrual phases.

Figure S2. The boxplots for the IHC scores of VEGF (A–C), MVD (D–F) and Slug (G–I) in normal endometria (A, D, G), eutopic endometria (B, E, H) and adenomyosis (C, F, I) in different menstrual phases.

Figure S3. Correlation between serum E2 levels and angiogenesis markers in normal endometria, eutopic endometria and adenomyotic lesions.

Figure S4. Western blot of the VEGF in Ishikawa cells after treatment with the different concentration of E2 for 24 hrs.

Figure S5. Haematoxylin & Eosin stain (HE) and the immunohistochemistry of VEGF and CD31 of the implanted adenomyotic lesions in the E2+ raloxifene animal experiments (see Fig. 6A–D).

Figure S6. Haematoxylin & Eosin stain (HE) and the immunohistochemistry of VEGF and CD31 of the implanted adenomyotic lesions in the E2+ bevacizumab animal experiments (see Fig. 6E–H).

Table S1. List of proteins tested by antibodies and characteristics of the corresponding antibodies used.

Table S2. Sequence of the oligonucleotides for shRNA construct making.

Table S3. Distribution of menstrual phases in samples from patients with adenomyosis and normal control.

Table S4. Serum E2 level in different menstrual phases of adenomyosis patients and normal control cases.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.